Piper sees GLP-1s increasing demand for knee/hip surgeries near-term (NYSE:NVO)

Mohammed Haneefa Nizamudeen/iStock via Getty Images

Piper Sandler said it expects upcoming results from a Novo Nordisk (NVO) study of its weight-loss drug semaglutide in the treatment of osteoarthritis to be “mediocre” and demand for knee and hip replacements to increase near-term as more patients qualify for

demandGLP1sIncreasingkneehipneartermNYSENVOPiperSeessurgeries
Comments (0)
Add Comment